Valbenazine Oral Capsule

Phase 2

Neurocrine Biosciences, Inc. (NBIX)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Feb '27

NBIXPhase 2$14.3B

Valbenazine Oral Capsule Phase 2 Est. Readout

Valbenazine Oral Capsule• Trichotillomania (Hair-Pulling Disorder)20

Feb 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Trichotillomania (Hair-Pulling Disorder)

View Full Landscape

Drug Information

Target Indication

Trichotillomania (Hair-Pulling Disorder)

Clinical Trial

NCT05207085

Last updated: 10/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

NBIX

Neurocrine Biosciences, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

NBI-1065845Phase 3

Major Depressive Disorder

Chronocort®Phase 3

Congenital Adrenal Hyperplasia

CrinecerfontPhase 3

Congenital Adrenal Hyperplasia

ValbenazinePhase 3

Tardive Dyskinesia

NBI-98854Phase 3

Tardive Dyskinesia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts